KCNH2 pharmacogenomics summary

Pharmacogenetics and Genomics

Volumn 20, Issue 12, 2010, Pages 775-777

  Oshiro, Connie ^a   Thorn, Caroline F ^a   Roden, Dan M ^c   Klein, Teri E ^a   Altman, Russ B ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

hERG protein; human; KCNH2 MeSH: C500089; long QT syndrome MeSH: D008133; LQTS; MeSH entry term: HERG protein; MeSH entry term: KCNH2 potassium channel; MeSH: C500089; pharmacogenomics; QT prolonging drugs

Indexed keywords

POTASSIUM CHANNEL HERG;

DRUG RESPONSE; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; HUMAN; KCNH2 GENE; LONG QT SYNDROME; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW;

ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77950361453     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283349e9c     Document Type: Review

References (50)

1. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350:1013-1022.
2. Kr potassium channel. Cell 1995; 81:299-307.
3. Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol 2007; 22:39-43.
4. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006; 440:463-469.
5. Maron BJ, Clark CE, Goldstein RE, Epstein SE. Potential role of QT interval prolongation in sudden infant death syndrome. Circulation 1976; 54:423-430.
6. Mitcheson JS. hERG potassium channels and the structural basis of drug-induced arrhythmias. Chem Res Toxicol 2008; 21:1005-1010.
7. Pearlstein R, Vaz R, Rampe D. Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K + channel. A model for bad behavior. J Med Chem 2003; 46:2017-2022.
8. Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towbin J, Vincent GM. Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation 1996; 94:1996-2012.
9. Kamiya K, Niwa R, Morishima M, Honjo H, Sanguinetti MC. Molecular determinants of hERG channel block by terfenadine and cisapride. J Pharmacol Sci 2008; 108:301-307.
10. Perry M, de Groot MJ, Helliwell R, Leishman D, Tristani-Firouzi M, Sanguinetti MC, Mitcheson J. Structural determinants of HERG channel block by clofilium and ibutilide. Mol Pharmacol 2004; 66:240-249.
11. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 2000; 97:12329-12333.
12. Eddy CA, MacCormick JM, Chung SK, Crawford JR, Love DR, Rees MI, et al. Identification of large gene deletions and duplications in KCNQ1 and KCNH2 in patients with long QT syndrome. Heart Rhythm 2008; 5:1275-1281.
13. Koopmann TT, Alders M, Jongbloed RJ, Guerrero S, Mannens MM, Wilde AA, Bezzina CR. Long QT syndrome caused by a large duplication in the KCNH2 (HERG) gene undetectable by current polymerase chain reaction-based exon-scanning methodologies. Heart Rhythm 2006; 3:52-55.
14. Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002; 105:1943-1948.
15. Kannankeril PJ, Roden DM, Norris KJ, Whalen SP, George AL Jr, Murray KT. Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives. Heart Rhythm 2005; 2:134-140.
16. Pfeufer A, Sanna S, Arking DE, Muller M, Gateva V, Fuchsberger C, et al. Common variants at ten loci modulate the QT interval duration in the QTSCD Study. Nat Genet 2009; 41:407-414.
17. Pfeufer A, Jalilzadeh S, Perz S, Mueller JC, Hinterseer M, Illig T, et al. Common variants in myocardial ion channel genes modify the QT interval in the general population: results from the KORA study. Circ Res 2005; 96:693-701.
18. Newton-Cheh C, Eijgelsheim M, Rice KM, de Bakker PI, Yin X, Estrada K, et al. Common variants at ten loci influence QT interval duration in the QTGEN Study. Nat Genet 2009; 41:399-406.
19. Aronov AM. Predictive in silico modeling for hERG channel blockers. Drug Discov Today 2005; 10:149-155.
20. Netzer R, Ebneth A, Bischoff U, Pongs O. Screening lead compounds for QT interval prolongation. Drug Discov Today 2001; 6:78-84.
21. Fenichel RR, Malik M, Antzelevitch C, Sanguinetti M, Roden DM, Priori SG, et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 2004; 15:475-495.
22. Zhou Z, Vorperian VR, Gong Q, Zhang S, January CT. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J Cardiovasc Electrophysiol 1999; 10:836-843.
23. Fitzgerald PT, Ackerman MJ. Drug-induced torsades de pointes: the evolving role of pharmacogenetics. Heart Rhythm 2005; 2:S30-S37.
24. Mohammad S, Zhou Z, Gong Q, January CT. Blockage of the HERG human cardiac K + channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 1997; 273:H2534-H2538.
25. Cubeddu LX. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther 2003; 10:452-457.
26. Sun Z, Milos PM, Thompson JF, Lloyd DB, Mank-Seymour A, Richmond J, et al. Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes. J Mol Cell Cardiol 2004; 37:1031-1039.
27. Finlayson K, Turnbull L, January CT, Sharkey J, Kelly JS. [3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. Eur J Pharmacol 2001; 430:147-148.
28. Wisialowski T, Crimin K, Engtrakul J, O'Donnell J, Fermini B, Fossa AA. Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability. J Pharmacol Exp Ther 2006; 318:352-359.
29. Perrin MJ, Kuchel PW, Campbell TJ, Vandenberg JI. Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-a-go-go-related gene channels. Mol Pharmacol 2008; 74:1443-1452.
30. Thomas D, Gut B, Wendt-Nordahl G, Kiehn J. The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. J Pharmacol Exp Ther 2002; 300:543-548.
31. Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther 2006; 316:1098-1106.
32. Sakaguchi T, Itoh H, Ding WG, Tsuji K, Nagaoka I, Oka Y, et al. Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient with the HERG mutation. J Pharmacol Sci 2008; 108:462-471.
33. Eap CB, Crettol S, Rougier JS, Schlapfer J, Sintra Grilo L, Deglon JJ, et al. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther 2007; 81:719-728.
34. Kongsamut S, Kang J, Chen XL, Roehr J, Rampe D. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol 2002; 450:37-41.
35. Hayashi K, Shimizu M, Ino H, Yamaguchi M, Terai H, Hoshi N, et al. Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG. Clin Sci (Lond) 2004; 107:175-182.
36. Kim KS, Kim EJ. The phenothiazine drugs inhibit hERG potassium channels. Drug Chem Toxicol 2005; 28:303-313.
37. Duncan RS, McPate MJ, Ridley JM, Gao Z, James AF, Leishman DJ, et al. Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin. Biochem Pharmacol 2007; 74:425-437.
38. Ridley JM, Milnes JT, Benest AV, Masters JD, Witchel HJ, Hancox JC. Characterisation of recombinant HERG K + channel blockade by the Class Ia antiarrhythmic drug procainamide. Biochem Biophys Res Commun 2003; 306:388-393.
39. Kang J, Wang L, Chen XL, Triggle DJ, Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K + channel HERG. Mol Pharmacol 2001; 59:122-126.
40. Cordes JS, Sun Z, Lloyd DB, Bradley JA, Opsahl AC, Tengowski MW, et al. Pentamidine reduces hERG expression to prolong the QT interval. Br J Pharmacol 2005; 145:15-23.
41. Ficker E, Kuryshev YA, Dennis AT, Obejero-Paz C,Wang L, Hawryluk P, et al. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 2004; 66:33-44.
42. Anson BD, Ackerman MJ, Tester DJ, Will ML, Delisle BP, Anderson CL, January CT. Molecular and functional characterization of common polymorphisms in HERG (KCNH2) potassium channels. Am J Physiol Heart Circ Physiol 2004; 286:H2434-H2441.
43. Larsen LA, Andersen PS, Kanters J, Svendsen IH, Jacobsen JR, Vuust J, et al. Screening for mutations and polymorphisms in the genes KCNH2 and KCNE2 encoding the cardiac HERG/MiRP1 ion channel: implications for acquired and congenital long Q-T syndrome. Clin Chem 2001; 47:1390-1395.
44. Paavonen KJ, Chapman H, Laitinen PJ, Fodstad H, Piippo K, Swan H, et al. Functional characterization of the common amino acid 897 polymorphism of the cardiac potassium channel KCNH2 (HERG). Cardiovasc Res 2003; 59:603-611.
45. Laitinen P, Fodstad H, Piippo K, Swan H, Toivonen L, Viitasalo M, et al. Survey of the coding region of the HERG gene in long QT syndrome reveals six novel mutations and an amino acid polymorphism with possible phenotypic effects. Hum Mutat 2000; 15:580-581.
46. Bezzina CR, Verkerk AO, Busjahn A, Jeron A, Erdmann J, Koopmann TT, et al. A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization. Cardiovasc Res 2003; 59:27-36.
47. Marjamaa A, Newton-Cheh C, Porthan K, Reunanen A, Lahermo P, Vaananen H, et al. Common candidate gene variants are associated with QT interval duration in the general population. J Intern Med 2009; 265:448-458.
48. Gentile S, Martin N, Scappini E, Williams J, Erxleben C, Armstrong DL. The human ERG1 channel polymorphism, K897T, creates a phosphorylation site that inhibits channel activity. Proc Natl Acad Sci USA 2008; 105:14704-14708.
49. Sinner MF, Pfeufer A, Akyol M, Beckmann BM, Hinterseer M, Wacker A, et al. The non-synonymous coding IKr-channel variant KCNH2-K897T is associated with atrial fibrillation: results from a systematic candidate gene-based analysis of KCNH2 (HERG). Eur Heart J 2008; 29:907-914.
50. Chevalier P, Bellocq C, Millat G, Piqueras E, Potet F, Schott JJ, et al. Torsades de pointes complicating atrioventricular block: evidence for a genetic predisposition. Heart Rhythm 2007; 4:170-174.